In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...

Deep within the cellular landscape, a quiet failure was taking place, impeding a potentially successful form of cancer ...

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 ...

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 ...

InxMed Co., Ltd ('InxMed'), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting ...

CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy ...

Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing ...

Chronic respiratory diseases substantially magnify pneumococcal pneumonia and invasive disease risk, with especially high CAP ...

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...

DUALITYBIO Inc. (HKEX: 09606; "DualityBio" or the "Company") today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next ...

Duality Biotherapeutics, Inc. ( 9606.HK) on Friday announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group, to develop ...

Investigators evaluated the efficacy and safety of immune checkpoint inhibitors in high-risk patients with genitourinary cancers and advanced chronic kidney disease.